Pharma major Dr. Reddy’s Laboratories on Tuesday said it has launcheda generic version of Ciprodex (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Otic Suspension, USP, in the U.S. market.
A therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, the product is indicated for treatment of bacterial ear infections in children. Ciprodex is a trademark of Bayer AG.
The launch follows the U.S. Food and Drug Administration (USFDA) approval for its product, Dr. Reddy’s said. Ciprodex brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ended June 2020, the company said citing IQVIA Health numbers.
“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” said Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.
“This product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form,” he said. Dr. Reddy’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle, a release said.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
